Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) EBT (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBT data on record, last reported at $2.2 million in Q3 2025.

  • For Q3 2025, EBT fell 41.74% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $6.5 million, up 167.63%, while the annual FY2024 figure was $4.2 million, 51.51% down from the prior year.
  • EBT reached $2.2 million in Q3 2025 per PLX's latest filing, up from $661000.0 in the prior quarter.
  • Across five years, EBT topped out at $19.6 million in Q2 2023 and bottomed at -$11.4 million in Q2 2021.
  • Average EBT over 5 years is -$839000.0, with a median of -$2.9 million recorded in 2023.
  • The widest YoY moves for EBT: up 2433.33% in 2021, down 500.34% in 2021.
  • A 5-year view of EBT shows it stood at $8.1 million in 2021, then tumbled by 139.85% to -$3.2 million in 2022, then tumbled by 100.19% to -$6.4 million in 2023, then skyrocketed by 213.85% to $7.3 million in 2024, then tumbled by 69.4% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $2.2 million in Q3 2025, $661000.0 in Q2 2025, and -$3.7 million in Q1 2025.